| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/10/2013 | CN101657432B Dihydro-benzo[B][1,4]diazepin-2-one sulfonamide derivatives |
| 04/10/2013 | CN101605784B Aza-bridged-ring compound |
| 04/10/2013 | CN101585777B Method for preparing a Venlafaxine hydrochloride crystal FormaI |
| 04/10/2013 | CN101492384B Uses of aminosalicylic acid derivative as neuroprotective agent |
| 04/10/2013 | CN101325871B Use of low-dose Ladostigil for neuroprotection |
| 04/10/2013 | CN101291925B Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists |
| 04/09/2013 | US8415355 Pyrrolopyrimidine compounds and their uses |
| 04/09/2013 | US8415303 Method of treatment using a soluble human delta protein fragment |
| 04/09/2013 | US8414916 Chewable soft capsule |
| 04/09/2013 | US8414894 Human antibodies that bind human TNFα and methods of using same |
| 04/09/2013 | CA2749172C Re-epithelializing pharmaceutical compositions comprising xanthan gum |
| 04/09/2013 | CA2746788C Modafinil polymorphic forms |
| 04/09/2013 | CA2601935C Nk1 antagonists |
| 04/09/2013 | CA2600628C Combination of egf/ghrp-6 for neurogeneration of central nervous system following autoimmune damage |
| 04/09/2013 | CA2588881C Potentiators of glutamate receptors |
| 04/09/2013 | CA2566601C Carboxamido opioid compounds |
| 04/09/2013 | CA2561555C Bicyclic aromatic sulfinyl derivatives |
| 04/09/2013 | CA2513915C New arylpiperazinyl compounds |
| 04/09/2013 | CA2451116C Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsaturated fatty acids from microbes, genetically modified plant seeds and marine organisms |
| 04/09/2013 | CA2383470C Inhibition of secretion from non-neuronal cells |
| 04/04/2013 | WO2013049686A1 Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders |
| 04/04/2013 | WO2013049523A1 Methods for reducing a-beta-1-42 levels, methods for reducing or preventing formation of amyloid plaques, and methods for improving cognitive function and memory retention in a subject |
| 04/04/2013 | WO2013049362A2 Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis |
| 04/04/2013 | WO2013049174A1 Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers |
| 04/04/2013 | WO2013049119A1 Selective nr2b antagonists |
| 04/04/2013 | WO2013049021A1 Process for the preparation of sulfamide derivatives |
| 04/04/2013 | WO2013048949A2 Selective nr2b antagonists |
| 04/04/2013 | WO2013047846A1 Glycosylated polypeptide and pharmaceutical composition containing same |
| 04/04/2013 | WO2013047701A1 Phenyl derivative |
| 04/04/2013 | WO2013047410A1 Long-acting adhesive skin patch for treating alzheimer's disease, and method for producing same |
| 04/04/2013 | WO2013047082A1 Exogenous opioid peptide-degrading enzyme |
| 04/04/2013 | WO2013047055A1 Heat shock protein expression inducer |
| 04/04/2013 | WO2013046029A1 Macrocyclic lrrk2 kinase inhibitors |
| 04/04/2013 | WO2013045891A1 A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (cbdv) and cannabidiol (cbd) |
| 04/04/2013 | WO2013045681A1 Improved process for the preparation of sulfamide derivatives |
| 04/04/2013 | WO2013045652A1 Inhibition of microrna-134 for the treatment of seizure-related disorders and neurologic injuries |
| 04/04/2013 | WO2013045607A1 Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors |
| 04/04/2013 | WO2013045452A1 Substituted methanesulfonamide derivatives as vanilloid receptor ligands |
| 04/04/2013 | WO2013045451A1 Amine substituted methanesulfonamide derivatives as vanilloid receptor ligands |
| 04/04/2013 | WO2013045380A2 Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification |
| 04/04/2013 | WO2013021196A3 Oligodendrocyte differentiation |
| 04/04/2013 | WO2013020722A3 Composition comprising small peptide as amyloid beta mimotope and adjuvant for use as vaccine against alzheimer's disease |
| 04/04/2013 | WO2013019711A3 NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS |
| 04/04/2013 | WO2013018091A8 Particles for the treatment of neurodegenerative diseases |
| 04/04/2013 | WO2013014204A3 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals |
| 04/04/2013 | WO2012177903A3 Methods of treating cognitive impairment |
| 04/04/2013 | WO2012170917A3 Reduction of microglia-mediated neurotoxicity by kv1.3 inhibition |
| 04/04/2013 | WO2012170452A3 Compositions and methods for treating neurodegenerative diseases |
| 04/04/2013 | WO2012161622A3 Incretin hormone secretion stimulators, method for producing and using same |
| 04/04/2013 | WO2012137982A3 Sulfonamide derivative and use thereof |
| 04/04/2013 | WO2012128799A3 Treating schizophrenia |
| 04/04/2013 | US20130085176 Process for the preparation of sulfamide derivatives |
| 04/04/2013 | US20130085175 Process for the preparation of sulfamide derivatives |
| 04/04/2013 | US20130085171 Compounded transdermal pain management |
| 04/04/2013 | US20130085167 Methods for treating a stroke-related sensorimotor impairment using aminopyridines |
| 04/04/2013 | US20130085166 Formulations and uses of retinoic acid receptor selective agonists |
| 04/04/2013 | US20130085156 Novel 2-pyridinecarboxamide derivatives |
| 04/04/2013 | US20130085138 Selective NR2B Antagonists |
| 04/04/2013 | US20130084289 Treatment of multiple sclerosis |
| 04/04/2013 | CA2850513A1 Process for the preparation of sulfamide derivatives |
| 04/04/2013 | CA2850469A1 Glycosylated polypeptide and pharmaceutical composition containing same |
| 04/04/2013 | CA2850367A1 Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders |
| 04/04/2013 | CA2850350A1 Macrocyclic lrrk2 kinase inhibitors |
| 04/04/2013 | CA2850258A1 Inhibition of microrna-134 for the treatment of seizure-related disorders and neurologic injuries |
| 04/04/2013 | CA2850015A1 Improved process for the preparation of sulfamide derivatives |
| 04/04/2013 | CA2849933A1 Substituted methanesulfonamide derivatives as vanilloid receptor ligands |
| 04/04/2013 | CA2849350A1 Amine substituted methanesulfonamide derivatives as vanilloid receptor ligands |
| 04/04/2013 | CA2849000A1 Phenyl derivative |
| 04/04/2013 | CA2845677A1 A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (cbdv) and cannabidiol (cbd) |
| 04/03/2013 | EP2574607A1 PDE10 modulators |
| 04/03/2013 | EP2574345A1 Humanized antibodies to amyloid beta |
| 04/03/2013 | EP2574342A1 Chlorite in the treatment of neurodegenerative disease |
| 04/03/2013 | EP2574172A2 Materials and methods for treatment of inflammation |
| 04/03/2013 | CN1989244B Inhibitors of tgf-r signaling for treatment of cns disorders |
| 04/03/2013 | CN1935258B West nile vaccine |
| 04/03/2013 | CN103025758A IL-1 binding proteins |
| 04/03/2013 | CN103025744A Aza-bicyclic amine n-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs |
| 04/03/2013 | CN103025732A Cis-tetrahydrospiro(cyclohexane-1,1'-pyrido[3,4-b]indol)-4-amine derivatives |
| 04/03/2013 | CN103025731A 2-pyridyl substituted imidazoles as therapeutic alk5 and/or alk4 inhibitors |
| 04/03/2013 | CN103025724A 哌啶衍生物 Piperidine derivatives |
| 04/03/2013 | CN103025714A Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies |
| 04/03/2013 | CN103025705A Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same |
| 04/03/2013 | CN103025357A Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
| 04/03/2013 | CN103025354A Treatment drug for autoimmune diseases and allergic diseases |
| 04/03/2013 | CN103025339A Expression modulator for clock gene Period |
| 04/03/2013 | CN103025326A Methods of treating restless legs syndrome |
| 04/03/2013 | CN103025325A Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy |
| 04/03/2013 | CN103013922A Method for eliminating alpha-synuclein generated in Parkinson's model cells by using cadmium telluride quantum dots and application thereof |
| 04/03/2013 | CN103012596A Endomorphin-derived peptide with blood-brain barrier permeability as well as synthesis and application of endomorphin-derived peptide |
| 04/03/2013 | CN103012439A Benzoyl substituted thiazolo[3,2-b]-1,2,4-triazine derivative and application thereof |
| 04/03/2013 | CN103012438A Alkoxy substituted thiazolo [3,2-b]-1,2,4-triazine derivatives and application thereof |
| 04/03/2013 | CN103012416A Method for preparing high-purity nalmefene hydrochloride |
| 04/03/2013 | CN103012390A Indole derivatives as S1P1 receptor |
| 04/03/2013 | CN103012376A Amide derivatives |
| 04/03/2013 | CN103012345A Luteolin alpha crystal form substance, preparation method thereof as well as pharmaceutical composition and application thereof |
| 04/03/2013 | CN103012315A Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC) |
| 04/03/2013 | CN103012259A 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors |
| 04/03/2013 | CN103012254A Pyridone derivatives for modulating stress-activated protein kinase system |
| 04/03/2013 | CN103012200A Compound with beta-secretase inhibition function, preparation method and applications thereof |
| 04/03/2013 | CN103012192A Novel aceglutamide compound and pharmaceutical composition thereof |